Peter‐Martin Bruch

934 total citations
15 papers, 126 citations indexed

About

Peter‐Martin Bruch is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Peter‐Martin Bruch has authored 15 papers receiving a total of 126 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Peter‐Martin Bruch's work include Chronic Lymphocytic Leukemia Research (4 papers), Virus-based gene therapy research (3 papers) and CAR-T cell therapy research (3 papers). Peter‐Martin Bruch is often cited by papers focused on Chronic Lymphocytic Leukemia Research (4 papers), Virus-based gene therapy research (3 papers) and CAR-T cell therapy research (3 papers). Peter‐Martin Bruch collaborates with scholars based in Germany, United States and Switzerland. Peter‐Martin Bruch's co-authors include Sascha Dietrich, Wolfgang Huber, Ivan Berest, Judith B. Zaugg, Armando Reyes‐Palomares, Giovanni Palla, Christian Arnold, K. Rasmussen, Kristian Helin and R. Wigand and has published in prestigious journals such as Blood, Circulation Research and Cell Reports.

In The Last Decade

Peter‐Martin Bruch

13 papers receiving 125 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter‐Martin Bruch Germany	7	71	26	24	21	17	15	126
Suet Ling Felce United Kingdom	7	83 1.2×	19 0.7×	36 1.5×	43 2.0×	14 0.8×	7	135
Anna Ringler Austria	5	136 1.9×	38 1.5×	38 1.6×	29 1.4×	12 0.7×	5	185
Christina Sternberg Austria	6	145 2.0×	26 1.0×	33 1.4×	15 0.7×	10 0.6×	6	188
Javier R. Arango Spain	3	71 1.0×	38 1.5×	21 0.9×	24 1.1×	15 0.9×	3	113
Lora Dimitrova Germany	6	64 0.9×	22 0.8×	15 0.6×	19 0.9×	25 1.5×	12	96
Mai Q. Nguyen United States	6	91 1.3×	12 0.5×	38 1.6×	20 1.0×	23 1.4×	6	123
Marni B. McClure Japan	5	67 0.9×	9 0.3×	41 1.7×	11 0.5×	41 2.4×	7	123
Kishore Amin India	5	38 0.5×	10 0.4×	23 1.0×	19 0.9×	6 0.4×	6	72
Zach Herbert United States	5	61 0.9×	9 0.3×	18 0.8×	68 3.2×	16 0.9×	7	150
Saya H. Ebbesen United States	3	90 1.3×	9 0.3×	45 1.9×	13 0.6×	23 1.4×	3	123

Countries citing papers authored by Peter‐Martin Bruch

Since Specialization

Citations

This map shows the geographic impact of Peter‐Martin Bruch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter‐Martin Bruch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter‐Martin Bruch more than expected).

Fields of papers citing papers by Peter‐Martin Bruch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter‐Martin Bruch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter‐Martin Bruch. The network helps show where Peter‐Martin Bruch may publish in the future.

Co-authorship network of co-authors of Peter‐Martin Bruch

This figure shows the co-authorship network connecting the top 25 collaborators of Peter‐Martin Bruch. A scholar is included among the top collaborators of Peter‐Martin Bruch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter‐Martin Bruch. Peter‐Martin Bruch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Roider, Tobias, Norman Mack, Peter‐Martin Bruch, et al.. (2024). CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models. Blood. 144(7). 784–789. 7 indexed citations

Bruch, Peter‐Martin, Christoph Peter, Sanil Bhatia, et al.. (2024). Novel meriolin derivatives potently inhibit cell cycle progression and transcription in leukemia and lymphoma cells via inhibition of cyclin-dependent kinases (CDKs). Cell Death Discovery. 10(1). 279–279. 7 indexed citations

Li, Yinan, Alexandru‐Emil Matei, Andrea‐Hermina Györfi, et al.. (2024). Characterization of Vascular Niche in Systemic Sclerosis by Spatial Proteomics. Circulation Research. 134(7). 875–891. 19 indexed citations

Bruch, Peter‐Martin, et al.. (2024). Multiplexed Immunophenotyping of Lymphoma Tissue Samples. Methods in molecular biology. 2865. 375–393.

Herbst, Sophie A., Vladislav Kim, Tobias Roider, et al.. (2023). Comparing the value of mono- vs coculture for high-throughput compound screening in hematological malignancies. Blood Advances. 7(19). 5925–5936. 7 indexed citations

Chen, Qian, Peter‐Martin Bruch, Carolin Kolb, et al.. (2023). Improving Anti-Tumor Efficacy of CAR T-Cell Therapy for Acute Myeloid Leukemia (AML): Results from a Multi-Drug Interaction Screening Approach. Blood. 142(Supplement 1). 5969–5969. 1 indexed citations

Bruch, Peter‐Martin, Carolin Kolb, Sophie A. Herbst, et al.. (2022). Drug‐microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL. Molecular Systems Biology. 18(8). e10855–e10855. 10 indexed citations

Öztürk, Selcen, Irene Gil-Fariña, Anna Jauch, et al.. (2021). Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients. Leukemia. 36(2). 464–475. 6 indexed citations

Berest, Ivan, Christian Arnold, Armando Reyes‐Palomares, et al.. (2019). Quantification of Differential Transcription Factor Activity and Multiomics-Based Classification into Activators and Repressors: diffTF. Cell Reports. 29(10). 3147–3159.e12. 59 indexed citations

10.

Bruch, Peter‐Martin, Carolin Kolb, Sophie Rabe, et al.. (2019). Systematic Investigation of Microenvironmental Drug Resistance Mechanisms in Chronic Lymphocytic Leukemia. Blood. 134(Supplement_1). 3363–3363.

11.

Roider, Tobias, Felix Frauhammer, Julian Seufert, et al.. (2019). TRANSCRIPTIONAL AND GENOMIC INTRA‐TUMOR HETEROGENEITY DRIVES SUBCLONE SPECIFIC DRUG RESPONSES IN DIFFUSE LARGE B CELL LYMPHOMA. Hematological Oncology. 37(S2). 75–77. 1 indexed citations

12.

Kuhn, J, et al.. (1984). Laboratoriumspraxis bei Adenoviren. Zentralblatt für Bakteriologie Mikrobiologie und Hygiene 1 Abt Originale A Medizinische Mikrobiologie Infektionskrankheiten und Parasitologie. 257(3). 426–432. 3 indexed citations

13.

Kühn, Joachim, et al.. (1984). [Laboratory methods for adenoviruses. XI. Determination of hexon and antihexon-IgA in conjunctival secretions using ELISA].. PubMed. 257(3). 426–32. 1 indexed citations

14.

Wigand, R., et al.. (1979). [Virological diagnosis of epidemic keratoconjunctivitis (author's transl)].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 245(3). 395–408. 2 indexed citations

15.

Wigand, R., et al.. (1975). [The etiology of epidemic keratoconjunctivities (author's transl)].. PubMed. 167(6). 823–9. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact